ChromaTan Inc. and Landmark Bio PBLLC have been awarded a grant from the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) to support the development of a recombinant adeno-associated virus (AAV) production process as part of NIIMBL’s Viral Vector Manufacturing and Analytics Program.

The NIIMBL award will enable ChromaTan and Landmark Bio to create a scalable and accessible platform for the manufacturing and characterization of AAV-based gene therapy vectors. 

The collaboration will leverage ChromaTan’s BioRMB technology and Kascade instrumentation, along with Landmark Bio’s knowledge in viral vector process development, chemistry, manufacturing and controls, and GMP manufacturing to improve purification efficiency and process intensification.

Oleg Shinkazh, chief executive officer of ChromaTan said,  “This grant will enable development of our advanced manufacturing technology for multiple AAV serotypes, evaluation of their key process variables as well as manufacturability. Being able to share our findings not just with our partner but also with the broader NIIMBL community is incredibly gratifying.”